23andMe pilots program to raise awareness about Lipoprotein(a)

In support of Lipoprotein(a) Awareness Day, 23andMe Holding (ME) announced a collaboration with Novartis Pharmaceuticals Corporation (NVS) to increase awareness for Lipoprotein(a). High levels of Lp(a) are associated with increased risk of heart attack, stroke and other life threatening conditions. The level of Lp(a), which can be detected through a simple blood test, is almost entirely determined by genes and is unrelated to diet, exercise or obesity, creating the need for greater awareness. With support from Novartis, 23andMe is piloting a new program to educate its customers about the risks associated with high Lp(a). 23andMe customers will be able to purchase a confidential screening test for Lp(a) and will be provided the option to connect with clinicians through 23andMe’s telehealth service, Lemonaid Health.